SAMe Augmentation in Major Depressive Disorder: Clinical Trial
Can SAMe Help When Antidepressants Aren’t Enough?
A clinical trial published in the American Journal of Psychiatry examined S-Adenosyl Methionine (SAMe) augmentation in major depressive disorder for patients who had failed prior SSRI treatment. This important study by Papakostas and colleagues investigated SAMe as an adjunctive treatment in 73 patients with major depression who had inadequate response to selective serotonin reuptake inhibitor therapy at adequate doses for at least 6 weeks. The research addresses a critical clinical need, as treatment-resistant depression affects a significant portion of patients and requires effective augmentation strategies.